Condition: Liver Fat · Liver Fibrosis · Glycemic Control · Sponsor: Getz Pharma
Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH)
This description comes directly from the study's public registry record.
Muhammad Nabeed Tahir, MBBS · +923015376299 · nabeedtahir@getzpharma.com
Jahanzeb Kamal Khan, MBBS · +923201212945 · jahanzeb.kamal@getzpharma.com
Always discuss trial participation with your own doctor first.
| North west general hospital | Peshawar, KPK, Pakistan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05644717